Compares two immune drug combinations in advanced melanoma, studying blood and tumor responses
Studies immune responses in blood and tumor of adults with advanced melanoma.
Key facts
- Who runs it
- John Kirkwood
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Registry title
- Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 19 Nov 2025
- Expected to end
- 1 Nov 2031
- Type of study
- Observational, 2 groups
- Treatments tested
- Fianlimab + Cemiplimab
- Relatlimab + Nivolumab
- Record updated
- 26 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma that cannot be removed by surgery or has spread, who are already in the HCC 24-056 study and agree to give extra tumor and blood samples.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Melanoma that cannot be removed by surgery (locally advanced) or has spread (metastatic), with tumor spots that can be biopsied at least 3 times
Main reasons for not taking part
- People who do not qualify to enroll in the HCC 24-056 study cannot join
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Study participants who meet inclusion criteria for the HCC 24-056 study will be eligible for this study
- Participants must be willing to provide additional samples beyond what is required of them in HCC 24-056. These include:; 3 additional tumor biopsies; 3 additional blood draws
- Participants must have biopsiable non-target disease amenable to at least 3 biopsies
- Must have the ability to understand and the willingness to sign a written informed consent document
Who cannot take part
- Study participants who do not qualify to enroll in the HCC 24-056 study will not be eligible for this study; -
Where in United States
- UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Danielle L Bednarz, RNTaking people
About the trial
What the trial wants to find out
This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.
The 2 groups in the trial
- fianlimab + cemiplimab
Patients who received fianlimab + cemiplimab treatment under protocol NCT06246916.
- Opdualag (relatlimab + nivolumab)
Patients who received Opdualag (relatlimab + nivolumab) under protocol NCT06246916.
Treatment: Relatlimab + Nivolumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Dose-response Analysis of Nivolumab/Relatlimab in the Fixed-dosed Combination 'Opdualag' vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood for Participants With Unresectable or Metastatic Melanoma: A Corollary Study of HCC 24-056 (NCT06246916)
- Plain-language title
- Compares two immune drug combinations in advanced melanoma, studying blood and tumor responsesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 November 2025